Phase
Condition
Neurologic Disorders
Multiple Sclerosis
Bone Marrow Disorder
Treatment
cALD SR-B (Standard-Risk, Regimen B)
IMD Preparative Regimen
cALD SR-A (Standard-Risk, Regimen A)
Clinical Study ID
Ages < 55 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
0 through 55 years of age
Adequate graft available
Adequate organ function
Eligible Diseases:
Mucopolysaccharidosis Disorders:
MPS IH (Hurler syndrome)
MPS II (Hunter syndrome) if the patient has no or minimal evidence ofsymptomatic neurologic disease but is expected to have a neurologicphenotype
MPS VI (Maroteaux-Lamy syndrome)
MPS VII (Sly syndrome)
Glycoprotein Metabolic Disorders:
Alpha mannosidosis
Fucosidosis
Aspartylglucosaminuria
Sphingolipidoses and Recessive Leukodystrophies:
Globoid cell leukodystrophy
Metachromatic leukodystrophy
Niemann-Pick B patients (sphingomyelin deficiency)
Niemann-Pick C subtype 2
Peroxisomal Disorders:
Adrenoleukodystrophy with cerebral involvement
Zellweger syndrome
Neonatal Adrenoleukodystrophy
Infantile Refsum disease
Acyl-CoA-Oxidase Deficiency
D-Bifunctional enzyme deficiency
Multifunctional enzyme deficiency
Alpha-methylacyl-CoA Racmase Deficiency (AMACRD)
Mitochondrial Neurogastrointestingal Encephalopathy (MNGIE)
Severe Osteopetrosis (OP)
Hereditary Leukoencephalopathy with axonal spheroids (HDLS; CSF1R mutation)
Other Inherited Metabolic Disorders (IMD): Patients will also be considered whohave other life-threatening, rare lysosomal, peroxisomal or other similarinherited disorders characterized by white matter disease or other neurologicmanifestations for which there is rationale that transplantation would be ofbenefit, such as certain patients with Wolman's disease, GM1 gangliosidosis,I-cell disease, Tay-Sachs disease, Sandhoff disease or others.
Voluntary written consent
Exclusion
Exclusion Criteria:
Pregnancy - menstruating females must have a negative serum or urine pregnancy testwithin 14 days of study treatment start
Prior myeloablative chemotherapy exposure within 4 months of the start ofconditioning on this protocol (patients excluded for this reason may be eligible forother institutional protocols)
Uncontrolled bacterial, fungal or viral infections including HIV (including activeinfection with Aspergillus or other mold within 30 days)
Study Design
Connect with a study center
Masonic Cancer Center, University of Minnesota
Minneapolis, Minnesota 55455
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.